SEC Filings

SEC Filings

Filing date	Description	Form	View
Nov 10, 2022	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-22-000119.pdf 0001235802-22-000119.rtf 0001235802-22-000119.xls
Dec 20, 2022	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-22-000136.pdf 0001235802-22-000136.rtf 0001235802-22-000136.xls
Mar 07, 2023	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-23-000030.pdf 0001235802-23-000030.rtf 0001235802-23-000030.xls
Jul 06, 2023	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-23-000075.pdf 0001235802-23-000075.rtf 0001235802-23-000075.xls
Jul 19, 2023	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-23-000077.pdf 0001235802-23-000077.rtf 0001235802-23-000077.xls
Nov 08, 2023	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-23-000110.pdf 0001235802-23-000110.rtf 0001235802-23-000110.xls
Sep 23, 2010	Tender offer schedule and amendment filed by the issuer.	SC TO-I	View HTML 0001193125-10-215376.pdf 0001193125-10-215376.rtf 0001193125-10-215376.xls
May 27, 2016	Tender offer schedule and amendment filed by the issuer.	SC TO-I	View HTML 0001193125-16-605144.pdf 0001193125-16-605144.rtf 0001193125-16-605144.xls
Jun 22, 2021	Termination of registration under Section 12(g) or suspension of duty to file reports	15-12B	View HTML 0001104659-21-084121.pdf 0001104659-21-084121.rtf 0001104659-21-084121.xls
Sep 11, 2018	UPLOAD	UPLOAD	View HTML 0000000000-18-028256.pdf 0000000000-18-028256.rtf

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE